Abstracts tagged "methotrexate (MTX)"

Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
René-Marc Flipo¹, Alain Saraux², Christophe Hudry³, Cécile Gaujoux-Viala⁴, Eric Senbel⁵, Sonia Tropé⁶, Elena Zinovieva⁷, Agnès Courbeyrette⁸ and Hélène Herman-Demars⁷, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology, CHU Brest, Brest, France, ³AP-HP Hôpital Cochin, Paris, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology office, Marseille, France, ⁶149 avenue du Maine, ANDAR, Paris, France, ⁷Medical Department Nordic Pharma, Paris, France, ⁸Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…
Abstract Number: 2446 • 2018 ACR/ARHP Annual Meeting
The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate
Sho Sasaki¹, Yasushi Kondo², Yasuo Suzuki³, Takayoshi Kurabayashi¹, Yasushi Koyama¹, Yuto Izumi¹, Yoko Nakagome¹, Kazuki Hirano¹, Chiho Yamada¹ and Shinji Sato¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokai University Hachioji Hospital, Hachioji, Japan, Isehara, Japan
Background/Purpose: Lymphoproliferative disorders (LPDs) are a serious complication in patients with rheumatoid arthritis (RA). Methotrexate (MTX) is known to be able to cause a development…
Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Yoko Shimizu¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani^1,3, Moeko Ochiai¹, Rei Yamaguchi¹, Naoki Sugimoto¹, Ayako Nakajima^1,3, Katsunori Ikari¹, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ³Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…
Abstract Number: 630 • 2018 ACR/ARHP Annual Meeting
Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
René-Marc Flipo¹, Eric Senbel², Sonia Tropé³, Elena Zinovieva⁴, Agnès Courbeyrette⁵ and Hélène Herman-Demars⁴, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology office, Marseille, France, ³149 avenue du Maine, ANDAR, Paris, France, ⁴Medical Department Nordic Pharma, Paris, France, ⁵Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: Previous studies have shown, that switching from oral to subcutaneous (SC) MTX can lead to improved efficacy and bioavailability (especially for doses ≥15mg/wk) as…
Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Christopher T. Ritchlin¹, Joseph F. Merola², Amanda M. Gellett³, Chen-Yen Lin³ and Talia Muram³, ¹University of Rochester Medical Center, Rochester, NY, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Michael D. George¹, Joshua Baker² and Alexis Ogdie³, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu², Meghan Glynn², Kelechi Emeanuru², Leslie R Harrold³, Sven Richter⁴, Benoit Guerette⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celgene Corporation, Summit, NJ, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Tsutomu Takeuchi¹, Yoshiya Tanaka², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Mitsuhiro Rokuda⁶, Hiroyuki Izutsu⁶, Satoshi Ushijima⁶, Yuichiro Kaneko⁶, Teruaki Shiomi⁶ and Emi Yamada⁶, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 959 • 2018 ACR/ARHP Annual Meeting
The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System
Elizabeth Pahomov¹, Yuliya Belopolsky¹, Arshad Ali¹ and Robert Woodrick², ¹Internal Medicine, NorthShore University HealthSystem, Evanston, IL, ²Rheumatology, NorthShore University HealthSystem, Evanston, IL
Background/Purpose: MTX has become the cornerstone in treatment of many rheumatologic disorders including rheumatoid arthritis and psoriasis. Although MTX can have a profound impact on…
Abstract Number: 2819 • 2018 ACR/ARHP Annual Meeting
Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
Isaac Smith¹, Jie Wei², Yuqing Zhang³, Hyon K. Choi² and Marcy Bolster¹, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of premature cardiovascular events and mortality. Prospective general population studies have shown moderate alcohol consumption…
Abstract Number: 1419 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
Giorgia Martini¹, Gloria Fadanelli¹, Anna Agazzi¹, Fabio Vittadello¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Linear Scleroderma (LS) is the most common subtype of localized Scleroderma in children and the one most frequently associated with tissue damage and functional…
Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…
Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Helga Westerlind¹, Mateusz Maciejewski², Thomas Frisell³, Scott Jelinsky⁴, Daniel Ziemek⁵ and Johan Askling¹, ¹Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Systems Immunology, Inflammation & Immunology,, Pfizer, Cambridge, MA, ³Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Inflammation and Immunology, Pfizer Research and Development, Cambridge, MA, ⁵Systems Immunology, Inflammation & Immunology,, Pfizer, Berlin, Germany
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].